Please try another search
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.
Name | Age | Since | Title |
---|---|---|---|
Paul Donald Richard MacLeman | 55 | 2020 | Executive Chairman |
David Charles Foster | - | 2020 | MD, CEO, President & Executive Director |
Amy K. Patick | - | 2022 | Member of Scientific Advisory Board |
Albert Hansen | - | 2020 | Non-Executive Director |
David Lionel Brookes | 63 | 2020 | Independent Non-Executive Director |
Stephen J. Thomas | - | - | Member of Scientific Advisory Board |
Leigh Bernard Farrell | - | - | Chairman of Scientific Advisory Board |
Anna Lavelle | - | 2020 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review